thanks its looking good ..even i am amazed
							
						
					MY PICK IS ELN
				
					Collapse
				
			
		
	X
- 
	
	
	
	
		
	
	
	
	
	
 Originally posted by kingofthehill View Postspike so where do you see it going from here ?
 Been noticing it myself...And every time I see it show up on one of my scans...I think of you (seriously)...Nice to see you are still among the living King"Trade What Is Happening...Not What You Think Is Gonna Happen"
 
 Find Tomorrow's Winners At SharpTraders.com
 
 Follow Me On Twitter
 Comment
- 
- 
	
	
	
	
		
	
	
	
	
	
- 
	
	
	
	
		
	
	
	
	
	
 June 23, 2008
 ACTION
 Buy
 Elan Corporation (ADR) (ELN)
 Return Potential: 37%
 The future redefined; adding to Conviction Buy List
 Source of opportunity
 Elan announced the headlines of the phase II Alzheimer’s Disease study
 that showed a statistically significant result in APOE4 negative patients.
 Elan and partner Wyeth have what is likely to be an approvable drug for
 this patient group in due course. Further, as Bapineuzumab is effective in
 treating Alzheimer’s Disease, it could also be effective in pre-Alzheimer’s
 Disease conditions, providing an entry into the prophylactic market. In that
 scenario, our forecasts would be far too conservative. We view the phase II
 data announcement as an inflection point, which could catalyse other
 strategic initiatives for the group. We add Elan to our Conviction Buy List.
 Growth
 Returns *
 Multiple
 Volatility Volatility
 Multiple
 Returns *
 Growth
 Investment Profile: Elan Corporation (ADR)
 Low High
 Percentile 20th 40th 60th 80th 100th
 * Returns = Return on Capital For a complete description of the
 investment profile measures please refer to
 the disclosure section of this document.
 ELN
 Europe Biotechnology Peer Group Average
 Catalyst
 We view the presentation of the Bapineuzumab phase II data at the ICAD
 Meeting on July 29 as the most significant near-term catalyst for the stock.
 However, we continue to believe that the possibility of a sub-part E filing
 (potentially on interim phase III data) cannot be ruled out. Also, we view
 the announcement of the Bapineuzumab data as the trigger for
 announcing that Elan will build a manufacturing facility for Bapineuzumab,
 and for a potential sale of the EDT business and a potential re-financing of
 the group, which could significantly reduce its interest costs.
 Valuation
 We are increasing our 6-month risk-adjusted DCF-based target price from
 US$34.20 to US$45, based on increased sales forecasts for Bapineuzumab
 and on using a lower discount rate for lower risk parts of the business
 such as Tysabri, other marketed products and EDT. Our forecasts on
 Bapineuzumab assume 1 mn patients treated at peak (vs. more than 8 mn
 Rx for Alzheimer’s Disease drugs in the US alone, so far in 200 . .
 Key risks
 Risks to our view and target price include any PML cases with Tysabri and
 disappointing details of the Bapineuzumab data at ICAD.
 INVESTMENT LIST MEMBERSHIP
 Pan-Europe Buy List
 Pan-Europe Conviction Buy List
 Coverage View: Neutral
 Ireland:
 Biotechnology
 Key data Current
 Price ($) 32.95
 6 month price target ($) 45.00
 Upside/(downside) (%) 37
 Market cap ($ mn) 15,430.5
 Enterprise value ($ mn) 16,780.8
 12/07 12/08E 12/09E 12/10E
 Revenue ($ mn) New 759.4 1,195.8 1,792.7 2,577.6
 Revenue revision (%) 0.0 0.0 0.0 1.6
 EBIT ($ mn) New (265.3) (12.7) 295.6 561.7
 EBIT revision (%) 0.0 0.0 0.0 0.4
 EPS ($) New (0.86) (0.31) 0.35 0.95
 EPS ($) Old (0.86) (0.31) 0.35 0.94
 EV/EBITDA (X) NM 145.6 40.6 22.8
 P/E (X) NM NM 93.5 34.8
 Dividend yield (%) -- -- -- --
 FCF yield (%) (3.4) (2.0) (0.2) 1.5
 CROCI (%) -- 5.0 19.6 31.4
 Price performance chart
 16
 18
 20
 22
 24
 26
 28
 30
 32
 34
 Jun-07 Sep-07 Dec-07 Apr-08
 480
 500
 520
 540
 560
 580
 600
 620
 640
 660
 Elan Corporation (ADR) (L) FTSE World Europe (USD) (R)
 Share price performance (%) 3 month 6 month 12 month
 Absolute 59.9 53.3 55.9
 Rel. to FTSE World Europe (USD) 58.4 71.1 79.2
 Source: Company data, Goldman Sachs Research estimates, FactSet. Price as of 6/20/2008 close.
 Stephen McGarry Ph.D.
 +44(20)7774-1134 | [email protected] Goldman Sachs International
 Linden Townson
 +44(20)7552-5783 | [email protected] Goldman Sachs International
 Mick Readey
 +44(20)7552-3714 | [email protected] Goldman Sachs International
 The Goldman Sachs Group, Inc. does and seeks to do business with
 companies covered in its research reports. As a result, investors should
 be aware that the firm may have a conflict of interest that could affect
 the objectivity of this report. Investors should consider this report as
 only a single factor in making their investment decision. Customers in
 the US can receive independent, third-party research on companies
 covered in this report, at no cost to them, where such research is
 available. Customers can access this independent research at
 www.independentresearch.gs.com or call 1-866-727-7000. For Reg AC
 certification, see the text preceding the disclosures. For other important
 disclosures go to www.gs.com/research/hedge.html. Analysts
 employed by non-US affiliates are not required to take the NASD/NYSE
 analyst exam.
 Comment
- 
- 
	
	
	
	
		
	
	
	
	
	
 Give this guy some props for his call over 3 years ago. While I always say "don't fall in love with a stock", the King has shown that his devotion to ELN has made him some big buckaroos. Here's one stock that has done very well over the last 2 years.Originally posted by kingofthehill View PostThanks Shady , I am a buyer here, the market does not understand that this drug will be back in short time 3-6 months ..great buy here below $4.00
 
 more upside than SIRI or any other cheap stock i know of
 
 I have no puts at these prices..when the stock crosses $5.00 i will buy puts
 
 for insuurance=============================
 
 I am HUGE! Bring me your finest meats and cheeses.
 
 - $$$MR. MARKET$$$
 Comment
- 



 
							
						 
							
						
Comment